Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Crinetics Pharmaceuticals announced positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist for treating congenital adrenal hyperplasia (CAH). The drug demonstrated sustained androgen reductions while enabling patients to lower glucocorticoid supplementation to physiologically normal levels. Additional Phase 1b/2a data in ACTH-dependent Cushing's syndrome showed rapid cortisol reduction. The company is advancing atumelnant into late-phase clinical development with Phase 3 trials already underway.

06/14/2026, 4:30 PM • GlobeNewswire

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Crinetics Pharmaceuticals announced long-term clinical data from PATHFNDR-1 and PATHFNDR-2 trials showing that PALSONIFY (paltusotine) maintains effective acromegaly control for up to two years with stable IGF-1 levels, symptom control, and pituitary tumor stabilization. Additional data demonstrated improved biochemical control when PALSONIFY is combined with cabergoline. The drug was well-tolerated with no new safety signals identified.

06/14/2026, 2:45 PM • GlobeNewswire

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Crinetics Pharmaceuticals announced it will present six abstracts at the Endocrine Society's Annual Meeting (ENDO 2026) in June, including oral presentations featuring long-term efficacy and safety data for PALSONIFY (paltusotine) in acromegaly and Phase 2 results for investigational ACTH receptor antagonist atumelnant in congenital adrenal hyperplasia and Cushing's syndrome. The company also reported Q1 2026 net product revenue of $10.3 million for PALSONIFY with 232 enrollment forms.

06/02/2026, 4:55 AM • GlobeNewswire

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Neutrolis Inc., a clinical-stage biotech company focused on treating autoimmune and inflammatory diseases, announced the appointment of Caren Deardorf as Chief Business & Strategy Officer. Deardorf brings over 30 years of executive leadership experience in commercialization and product launches, previously serving as Chief Commercial & Strategy Officer at Editas Medicine, Magenta Therapeutics, and Ohana Biosciences. She will lead business development and commercial strategy as Neutrolis advances its NTR-1011 candidate following positive Phase 1a results.

04/15/2026, 2:00 PM • GlobeNewswire

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Pharmaceuticals announced it will report Q4 and full year 2025 financial results on February 26, 2026, with a management conference call at 4:30 p.m. ET. The company also recently initiated a Phase 2/3 pediatric trial for atumelnant in congenital adrenal hyperplasia and announced January 2026 inducement grants.

01/26/2026, 5:00 PM • GlobeNewswire

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals announced a conference call scheduled for January 5, 2026 to provide a commercialization update on PALSONIFY (paltusotine) and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. The company's lead product PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, while atumelnant is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

01/04/2026, 4:00 PM • GlobeNewswire

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Pharmaceuticals initiated a Phase 1/2 clinical trial for CRN09682, an investigational nonpeptide drug conjugate targeting somatostatin receptor type 2-positive neuroendocrine tumors, marking a significant milestone in developing a potentially more precise targeted therapy.

12/03/2025, 8:00 AM • GlobeNewswire

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday

Crinetics Pharmaceuticals reported Q3 earnings with lower-than-expected revenue and increased net losses, despite receiving FDA approval for its acromegaly treatment Palsonify and securing a licensing agreement with Sanwa Kagaku Kenkyusho.

11/07/2025, 4:16 PM • The Motley Fool

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals granted stock options and restricted stock units to 20 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan, with options and RSUs vesting over four years.

10/10/2025, 4:41 PM • GlobeNewswire

Is Crinetics Pharmaceuticals Stock a Buy?

Crinetics Pharmaceuticals received FDA approval for Palsonify, its first once-daily oral treatment for acromegaly, potentially generating $800 million to $1.5 billion in peak sales. However, commercial execution risks and limited patient pool create uncertainty about the drug's market success.

09/28/2025, 8:30 AM • The Motley Fool

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday

Multiple stocks saw significant gains on Friday, with Crinetics Pharmaceuticals leading the pack after FDA approval, while other companies like BlackBerry, Perpetua Resources, and Scholar Rock also experienced notable stock price increases.

09/26/2025, 10:23 AM • Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session

Multiple healthcare stocks experienced significant pre-market price movements, with some companies seeing notable gains while others faced declines.

09/26/2025, 8:10 AM • Benzinga

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Crinetics Pharmaceuticals presented long-term clinical data on PALSONIFY, an oral medication for acromegaly, showing sustained IGF-1 level control and stable patient symptoms across two Phase 3 clinical trials.

07/13/2025, 5:45 PM • GlobeNewswire